19 December 2017
: Case report
A Case of Osteonecrosis of the Jaw in a Patient with Crohn’s Disease Treated with Infliximab
Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Unusual setting of medical care, Unexpected drug reaction
Gianfranco Favia1AD, Angela Tempesta- B Data collection/entry
- E Preparation of manuscript
- F Literature analysis/search
- *Corresponding author: [email protected]
- B Data collection/entry
- E Preparation of manuscript
- F Literature analysis/search
- E Preparation of manuscript
- F Literature analysis/search
- A Study design/planning
- D Data interpretation
- A Study design/planning
- D Data interpretation
- A Study design/planning
- C Data analysis/statistics
- D Data interpretation
- F Literature analysis/search
DOI: 10.12659/AJCR.905355
Am J Case Rep 2017; 18:1351-1356
Abstract
BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, occurring in patients undergoing treatments with antiresorptive or antiangiogenic agents, such as bisphosphonates, denosumab, or bevacizumab, for different oncologic and non-oncologic diseases. The aim of this study was to report a case of MRONJ in a patient taking infliximab, an anti-TNF-???? antibody used to treat Crohn’s disease, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
CASE REPORT: A 49-year-old female patient affected by Crohn’s disease, who had been undergoing 250 mg intravenous infliximab every six weeks for 12 years, with no history of antiresorptive or antiangiogenic agent administration, came to our attention for post-surgical MRONJ, associated with a wide cutaneous necrotic area of her anterior mandible. Following antibiotic cycles, the patient underwent surgical treatment with wide bone resection and debridement of necrotic tissues; after prolonged follow-up (16 months), the patient completely healed without signs of recurrence.
CONCLUSIONS: Prevention of MRONJ by dental check-up before and during treatments with antiresorptive treatments (bisphosphonates or denosumab) is a well-established procedure. Although further studies are required to confirm the role of infliximab in MRONJ, based on the results of this study, we propose that patients who are going to be treated with infliximab should also undergo dental check-up before starting therapy, to possibly avoid MRONJ onset.
Keywords: Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Crohn Disease
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946839
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946674
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945853
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947512
Most Viewed Current Articles
21 Jun 2024 : Case report
96,276
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,197
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
31,128
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,383
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030